Patients’ lived experience of thymidine kinase 2 deficiency: the online survey-based assessment of TK2d patient perspectives study
Therapeutic Advances in Rare Disease · 2026-07 · 7
DOI: 10.1177/26330040261469197 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Rare Disease, online erschienen am 21.07.2026. Verfasst von Amel Karaa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Massachusetts General Hospital, Division of Genetics, Harvard Medical School, 175 Cambridge Street, Boston, MA 02114, USA. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: UCB.
Abstract (Originalsprache)
Background
Thymidine kinase 2 deficiency (TK2d) is an ultra-rare autosomal recessive mitochondrial disease characterized by progressive myopathy.
Objectives
To understand patient experiences and the impact of TK2d on patient quality of life (QoL), and to explore support needs.
Design
A cross-sectional international online survey.
Methods
The survey for the Assessment of TK2d Patient Perspectives (ATP) study, co-created with patient advocates, included multiple-choice questions, verbal rating scales, and open free-text questions. Patients of all ages with a self-reported genetic diagnosis of TK2d were eligible to participate, either directly or through a caregiver proxy. The patient, caregiver proxy, or bereaved caregiver proxy answered questions on demographics, signs/symptoms, impacts on health-related QoL (HRQoL), support needs, healthcare resource use, and overall experience of living with TK2d. Quantitative data were summarized with descriptive statistics. Qualitative data were analyzed using inductive thematic analysis.
Results
Responses for 32 patients (24 patient and 8 caregiver proxy responses) were collected between September 2023 and February 2024. All patients experienced myopathic symptoms. The most frequently reported impact of TK2d was on patients’ ability to perform basic activities of daily living (26/32), including difficulties in walking (22/32), eating/swallowing (19/32), and breathing (25/32). The proportions of patients reporting a moderate or severe impact of breathing and walking difficulties on HRQoL, and the proportions requiring medical devices, were higher for those with an earlier age of TK2d symptom onset (⩽2, vs >2 to ⩽12, or >12 years). For most patients, TK2d also had a negative impact on mood, social and leisure activities, and employment/education. Progressive loss of abilities, increasing dependency on others, and medical equipment use contributed to mental and emotional burdens.
Conclusion
These quantitative and qualitative analyses of patients’ lived experiences highlight the substantial, progressive, and wide-ranging burden of TK2d.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Massachusetts General Hospital, Division of Genetics, Harvard Medical School, 175 Cambridge Street, Boston, MA 02114, USA.
- UCB, Slough, Berkshire, UK.
- The Lily Foundation, Warlingham, UK.
- United Mitochondrial Disease Foundation, Pittsburgh, PA, USA.
- Rare Disease Research Partners, Amersham, UK.
- UCB, Smyrna, GA, USA.
ORCID-Profile: Amel Karaa, Asha Hareendran, Katie Waller, Cristy Balcells
Förderung
- UCB
Zitieren
APA
Karaa, A., Hareendran, A., Waller, K., Yeske, P., Morrison, A., Ross, M., & Balcells, C. (2026). Patients’ lived experience of thymidine kinase 2 deficiency: the online survey-based assessment of TK2d patient perspectives study. Therapeutic Advances in Rare Disease, 7. https://doi.org/10.1177/26330040261469197
Vancouver
Karaa A, Hareendran A, Waller K, Yeske P, Morrison A, Ross M, et al. Patients’ lived experience of thymidine kinase 2 deficiency: the online survey-based assessment of TK2d patient perspectives study. Therapeutic Advances in Rare Disease. 2026;7. doi:10.1177/26330040261469197
BibTeX
@article{Karaa2026,
author = {Karaa, Amel and Hareendran, Asha and Waller, Katie and Yeske, Philip and Morrison, Alexandra and Ross, Marnie and Balcells, Cristy},
title = {Patients’ lived experience of thymidine kinase 2 deficiency: the online survey-based assessment of TK2d patient perspectives study},
journal = {Therapeutic Advances in Rare Disease},
year = {2026},
volume = {7},
doi = {10.1177/26330040261469197}
}
EUVIMED